CLEC12A and myeloid neoplasm: Our data impact on the notion of CLEC12A as a druggable protein in myeloid malignancies, where the first open‐label, first‐in‐human phase 1 study of a bispecific CLEC12A‐CD3 antibody has been initiated in Europe (EudraCT number 2015‐003704‐23).